Biogen Inc. was upgraded from Sell to Hold following its $5.6 billion acquisition of Apellis, which adds near-term revenue and expands its kidney disease portfolio. While multiple sclerosis revenues remain stable, long-term decline is expected, and new product launches are not anticipated before 2028/2029. Setbacks in the Alzheimer's pipeline persist, but Biogen's low valuation, strong cash position, and merger and acquisition capacity offer some protection against downside risks through the decade.
Biogen's stock dropped 6.4% on May 14, 2026, following the release of Phase 2 CELIA trial data showing that diranersen failed to meet its primary dose-response endpoint. Despite this setback, Biogen plans to continue developing diranersen based on po...
Levi & Korsinsky has launched an investigation into Biogen Inc. following a significant stock drop after the CELIA trial for BIIB080 in early Alzheimer's disease failed to meet its primary endpoint. The trial's lack of statistical significance led to...
Biogen reported Phase 2 trial results for diranersen, a tau-targeting therapy for early Alzheimer’s, showing cognitive benefits and reduced tau biomarkers despite missing the primary endpoint. The drug slowed cognitive decline across doses, especiall...
Biogen has finalized its acquisition of Apellis Pharmaceuticals, gaining full ownership of two commercial products, EMPAVELI® and SYFOVRE®, which generated $689 million in revenue in 2025. This deal enhances Biogen's growth prospects and expands its ...
Biogen announced positive topline results from its Phase 2 CELIA study of diranersen, an investigational therapy targeting tau protein in early Alzheimer's disease. The study showed robust reductions in tau pathology and a slowing of cognitive declin...
